In a small company you must be able to wear many hats. The hats I am currently wearing at Bio-Thera Solutions include: 1) Business Development & Licensing A) Out-licensing> BAT1706 "global" commercialization partnership with Sandoz - >$150M upfront + milestones> BAT1706 commercialization partnership with Beigene for Greater China - $165M upfront + milestones> BAT1806 global commercialization partnership with Biogen - $30M upfront + milestones> BAT2206 US commercialization partnership with Hikma - $20M upfront + $130M milestones> BAT2206 commercialization partnership with Gedeon Richter - $8.5M upfront, $101.5 milestones> BAT2506 commercialization partnership with STADA for Europe - $10M upfront, $137.5 milestones> BAT1706 commercialization partnership with Biomm for Brazil> BAT1706 commercialization partnership with MEGA Biosciences for Indonesia> BAT1706 commercialization partnership with Macter for Pakistan and Afghanistan> BAT1706 commercialization partnership with Cipla for multiple international countries> BAT2206 commercialization partnership with Biomm for Brazil> BAT2206 commercialization partnership with Pharmpark for Russia and other CIS countries> BAT2506 commercialization partnership with SteinCares for LATAM> BAT2506 commercialization partnership with Pharmpark for Russia and other CIS countries> BAT2606 commercialization partnership with SteinCares for LATAM B) In-licensing> License Agreement with Intract Pharma for Soteria & Phloral Drug Delivery Technologies2) Global Corporate Communications - Press release strategy, writing and execution3) Marketing> Lead development of brand name Pobevcy for BAT1706 approved in China, US & EU> Lead development of brand name QLETLI for BAT1406 approved in China> Lead development of non-prop names for multiple assets

I provide business advice and consulting services to pharmaceutical and biotech companies regarding business development activities, patient advocacy activities, research and development and marketing activities.

I was responsible for all aspect of leadership, strategy, operations, marketing and business development of the largest Sarcoma patient advocacy group in the United States. Highlights of my accomplishments during my time at the SFA include:o P&L Responsibility; Increased revenue in 2106 and 2017 by more than 10%o Doubled unrestricted assets during 3 year periodo Manage a 7-person teamo Created "Race to Cure Sarcoma" signature fundraising events; grown to ten events in 2017 through partnerships with Academic Hospitalso Grew the SFA Patient Education Program from single event to ten events across the US in 2017 along with associated revenue stream through partnerships with Academic Hospitalso Partnered with Frontline Oncology to launch Sarcoma Scientific Journal in 2017 o Partnered with SARC and QuadW to fund a PD-1 clinical trial in 8 sarcoma subtypes o Partnered with AxisMed on CME Sarcoma Education Program with Toolkitso Partnered to develop and launch a patient self-care mobile appo Responsible for building partnerships with Pharmaceutical and Biotech companieso Set legislative and regulatory priorities for the organization; manage relationships with Pharmaceutical Trade Associations and Patient Policy Coalitionso Increased overall Sarcoma research grant funding to $1M per yearo Launched SFA's first radio Public Service Announcement Campaign